Entasis Therapeutics
Innoviva Specialty Therapeutics develops and delivers innovative therapies for patients in critical care and infectious disease, focusing on urgent needs such as serious, life-threatening conditions and emerging illnesses caused by drug-resistant microorganisms. The company is building a culture dedicated to saving lives through its portfolio of marketed products and development pipeline, led by a mission-driven team blending medical science with pharmaceutical innovation.
Industries
Nr. of Employees
medium (51-250)
Entasis Therapeutics
Patents
Products
Intravenous angiotensin II vasoconstrictor (marketed)
A parenteral angiotensin II product indicated to increase blood pressure in adults with septic or other distributive shock.
Eravacycline antibacterial for complicated intra-abdominal infections (marketed)
A tetracycline-class antibacterial indicated for treatment of complicated intra-abdominal infections in adults.
Co-packaged sulbactam plus beta‑lactamase inhibitor for IV use (marketed)
An intravenous co-packaged combination of a beta-lactam antibacterial and a beta-lactamase inhibitor indicated for hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter isolates.
Advanced-generation cephalosporin antibiotic for IV use (marketed)
An advanced-generation cephalosporin intravenous antibiotic indicated for bloodstream infections, skin and skin-structure infections, and community-acquired bacterial pneumonia.
Oral single-dose spiropyrimidinetrione antibiotic (investigational)
An investigational, first-in-class, single-dose oral antibiotic that inhibits bacterial type II topoisomerase, developed for the treatment of uncomplicated gonorrhea; submitted under NDA for regulatory review.
Intravenous angiotensin II vasoconstrictor (marketed)
A parenteral angiotensin II product indicated to increase blood pressure in adults with septic or other distributive shock.
Eravacycline antibacterial for complicated intra-abdominal infections (marketed)
A tetracycline-class antibacterial indicated for treatment of complicated intra-abdominal infections in adults.
Co-packaged sulbactam plus beta‑lactamase inhibitor for IV use (marketed)
An intravenous co-packaged combination of a beta-lactam antibacterial and a beta-lactamase inhibitor indicated for hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter isolates.
Advanced-generation cephalosporin antibiotic for IV use (marketed)
An advanced-generation cephalosporin intravenous antibiotic indicated for bloodstream infections, skin and skin-structure infections, and community-acquired bacterial pneumonia.
Oral single-dose spiropyrimidinetrione antibiotic (investigational)
An investigational, first-in-class, single-dose oral antibiotic that inhibits bacterial type II topoisomerase, developed for the treatment of uncomplicated gonorrhea; submitted under NDA for regulatory review.
Services
Provision of medical information to healthcare professionals and management of suspected adverse reaction reporting channels.
Collaborative clinical program management, regulatory filing support for NDAs and coordination with global public-health partners for pathogen‑targeted antibacterial candidates.
Execution of licensing and distribution agreements and coordination with specialty pharmacies and distributors to supply hospital and outpatient markets.
Preparation and presentation of clinical and preclinical data at scientific meetings and support for peer-reviewed publication.
Provision of in vitro susceptibility testing, synergy assays, ex vivo CRRT clearance studies, equivalency testing versus reference methods, and PK/PD analyses to support antibacterial development programs.
Provision of medical information to healthcare professionals and management of suspected adverse reaction reporting channels.
Collaborative clinical program management, regulatory filing support for NDAs and coordination with global public-health partners for pathogen‑targeted antibacterial candidates.
Execution of licensing and distribution agreements and coordination with specialty pharmacies and distributors to supply hospital and outpatient markets.
Preparation and presentation of clinical and preclinical data at scientific meetings and support for peer-reviewed publication.
Provision of in vitro susceptibility testing, synergy assays, ex vivo CRRT clearance studies, equivalency testing versus reference methods, and PK/PD analyses to support antibacterial development programs.
Expertise Areas
- Clinical trial management
- Antibacterial drug development (pathogen-targeted therapies)
- Regulatory strategy and multi-jurisdictional submissions
- Clinical microbiology and susceptibility surveillance
Key Technologies
- Randomized controlled Phase 3 trial design
- Non-inferiority statistical methods
- In vitro antimicrobial susceptibility testing (broth microdilution, disc diffusion)
- In vitro synergy testing